Matrix metalloproteinases in Hypertensive heart disease: New mechanistic insights

Hypertension Research

Volumn 31, Issue 6, 2008, Pages 1061-1062

  Ito, Takayuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiac remodoling; Extracellular matrix; Hypertension; Matrix metalloproteinases; Tissue inhibitors of matrix metalloproteinases

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; PG 11680; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGE DISTRIBUTION; CLINICAL TRIAL; DIASTOLIC HEART FAILURE; DISEASE MARKER; DRUG TOLERABILITY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; EXTRACELLULAR MATRIX; HEART DISEASES; HUMANS; HYPERTENSION; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 48349128908     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1061     Document Type: Note

References (11)

1. Berk BC, Fujiwara K, Lehoux S: ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568-575.
2. Iwanaga Y, Aoyama T, Kihara Y, et al: Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39: 1384-1391.
3. Mujumdar VS, Smiley LM, Tyagi SC: Avtivation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol 2001; 79: 277-286.
4. Matsusaka H, Ide T, Matsushima S, et al: Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006; 47: 711-717.
5. Heymans S, Lupu F, Terclavers S, et al: Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005;166:15-25.
6. Lin J, Davis HB, Dai Q, et al: Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008;31:1225-1231.
7. Hinujosa-Laborde C, Craig T, Zheng W, et al: Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 2004;44: 405-409.
8. Ahmed SH, Clark LL, Pennington WR, et al: Matfix metalloproteinase/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
9. Ishikawa J, Kario K, Matsui Y, et al: Collagen metabolism ni extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res 2005; 28: 995-1001.
10. Chapman RE, Spinale FG: Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 2004; 286: H1-H10.
11. Hudson MP, Armstrong PW, Ruzyllo W, et al: Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006; 48: 15-20.